Overview

Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Phase:

Phase 4

Details

Lead Sponsor:

Shahid Beheshti University of Medical Sciences

Treatments:

Cyclosporine
Cyclosporins